Author(s):
Shalini Yadav, Sunil Sharma, Bir Singh Yadav, Rohtash Insa
Email(s):
shalini17031990@gmail.com
DOI:
10.52711/0974-360X.2024.00796 
Address:
Shalini Yadav1*, Sunil Sharma1, Bir Singh Yadav2, Rohtash Insa3
1Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar – 125001, Haryana.
2Shanti Mission Hospital 49 E, Delhi Road, Model Town, Hisar – 125001.
3State Medical College, Uttar Pradesh.
*Corresponding Author
Published In:
Volume - 17,
Issue - 11,
Year - 2024
ABSTRACT:
Objectives: The study was designed to evaluate if antihypertensive drug compliance has a protective role against mild cognitive impairment (MCI). Further to assess the prevalence and factors associated with MCI among older adults in Indian population. Our study also focused on serum creatinine level correlation with blood pressure and cognitive impairment. Materials and Methods: The investigation was carried out at multi-specialty hospitals. The experimental protocol was approved by Ethical Committee constituted as per guidelines of Indian Council of Medical Research (ICMR). 168 subjects were enrolled, having age=50 years and with hypertension= 5 years; does not meet the diagnostic criteria for dementia as defined by ICD-10. Subjects were assessed by using Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) for MCI, further assessed by various cognitive domain specific tests. Statistical analysis: Analysis was done using SPSS software version 25.0. Results: Females dominated the study population with a mean age of 59.92± 8.52 yrs. 57.73 percent of population belongs to rural background. Cognitive impairment was more prevalent in non-complaint group (85.9%) than in compliant group (49%). Mean MMSE score of non-complaint group 25.53± 2.54 compared to 27.30± 1.90 in complaint group (p< 0.001) and mean MoCA score was 22.39± 3.28 compared to 24.93± 2.43 in complaint group (p< 0.001). Cognition sub- domains were found to be affected. Conclusion: In accordance with above study compliance/adherence to antihypertensive medicines indicates a protective effect on brain cognition. Because hypertension patients experience cognitive deterioration at a high rate, a thorough cognitive assessment is necessary as part of an overall evaluation.
Cite this article:
Shalini Yadav, Sunil Sharma, Bir Singh Yadav, Rohtash Insa. The Impact of Medication Compliance on mild Cognitive Impairment in Hypertensive Individuals: A Cohort Study. Research Journal of Pharmacy and Technology. 2024; 17(11):5201-6. doi: 10.52711/0974-360X.2024.00796
Cite(Electronic):
Shalini Yadav, Sunil Sharma, Bir Singh Yadav, Rohtash Insa. The Impact of Medication Compliance on mild Cognitive Impairment in Hypertensive Individuals: A Cohort Study. Research Journal of Pharmacy and Technology. 2024; 17(11):5201-6. doi: 10.52711/0974-360X.2024.00796 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-11-4
REFERENCES:
1. Gauthier S, et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet. 2006; 367: 1262–70. https://doi.org/10.1016/S0140-6736(06)68542-5
2. The ICD 10 classification of mental and behavioural disorders: Clinical description and diagnostic guidelines. In: F00-F09 organic, including symptomatic, mental disorder World Health Organization, Geneva. Printed in Switzerland. 1992; PP45- 56
3. Kalaria RN, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. The Lancet Neurology. 2008; 7: 812–26. DOI: 10.1016/S1474-4422(08)70169-8
4. Prince MJ, et al. World Alzheimer Report 2015- The global impact of dementia: An analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International. 2015: 84
5. Solfrizzi V, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004; 63(10): 1882–91. doi: 10.1212/01.wnl.0000144281.38555.e3
6. Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2224–2260. doi: 10.1016/S0140-6736(12)61766-8
7. Tzourio C, et al. Is hypertension associated with an accelerated aging of the brain? Hypertension. Lippincott Williams and Wilkins. 2014; 63: 894–903. doi: 10.1161/HYPERTENSIONAHA.113.00147
8. Ong KL, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49(1): 69–75. doi: 10.1161/01.HYP.0000252676.46043.18
9. Hughes D, et al. Association of Blood Pressure Lowering with Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020; 323: 1934–44. doi: 10.1001/jama.2020.4249
10. Chen C, Zissimopoulos JM. Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimer’s and Dementia: Translational Research and Clinical Interventions. 2018; 4: 510–20. doi: 10.1016/j.trci.2018.08.009
11. Wharton W, et al. Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer’s disease. J Am Geriatr Soc. 2015; 63(9): 1749–56. doi: 10.1111/jgs.13627
12. Barthold D, et al. Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk. PLoS ONE. 2020; 15(3): 1-15. doi: 10.1371/journal.pone.0229541
13. Goldstein FC, et al. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc. 2013; 61(1): 67–73. doi: 10.1111/jgs.12067
14. Li J, Wang YJ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011; 76: 1485–1491. doi: 10.1212/WNL.0b013e318217e7a4
15. Das SK, et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology. 2007; 68: 2019–2026. doi: 10.1212/01.wnl.0000264424.76759.e6
16. de Jong-Schmit BEM, et al. Blood pressure, antihypertensive medication and neuropsychiatric symptoms in older people with dementia: The COSMOS study. International Journal of Geriatric Psychiatry. 2021; 36(1): 46–53. doi: 10.1002/gps.5388
17. Diener HC, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. The Lancet Neurology. 2008; 7 (10): 875–84. doi: 10.1016/S1474-4422(08)70198-4
18. Bosch J, et al. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology. 2019; 92(13): E1435–46. doi: 10.1212/WNL.0000000000007174
19. Goins RT, et al. Cardiometabolic Conditions and All-Cause Dementia Among American Indian and Alaska Native People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2022; 77(2): 323–30. doi: 10.1093/gerona/glab097
20. Farron MR, et al. Hypertension and Cognitive Health Among Older Adults in India. J Am Geriatr Soc. 2020; 68(S3): S29–35. doi: 10.1111/jgs.16741.
21. Kearney PM, et al. Articles Introduction Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365: 217–23. doi: 10.1016/S0140-6736(05)17741-1.
22. Higuchi M, et al. Mid-life proteinuria and late-life cognitive function and dementia in elderly men: The Honolulu-Asia aging study. Alzheimer Dis Assoc Disord. 2015; 29: 200–5. doi: 10.1097/WAD.0000000000000082.
23. De Oliveira FF, et al. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease. Colombia Médica. 2016; 47. PMID: 27546928; PMCID: PMC4975126.
24. Morris JC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989; 39: 1159-1165. DOI: 10.1212/wnl.39.9.1159
25. Folstein MF, et al. “Mini-Mental State” A practical method for grading the cognitive state of patients for the clinicians. J. Psychiat. Res. 1975; 12: 189-198. doi: 10.1016/0022-3956(75)90026-6
26. Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53: 695–699. doi: 10.1111/j.1532-5415.2005.53221.x
27. Sivan, AB. Benton Visual Retention Test. 5th Edition. San Antonio, TX: The Psychological Corporation. 1992
28. Orsini A, et al. Verbal and spatial immediate memory span: Normative data from 1355 adults and 1112 children. J. Neurol. Sci. 1987; 8: 539-548. doi: 10.1007/BF02333660.
29. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills. @ Southern Universities Press. 1958; 8. https://doi.org/10.2466/pms.1958.8.3.271
30. Dhikav V, et al. Medication adherence survey of drugs useful in prevention of dementia of Alzheimer’s type among Indian patients. International Psychogeriatrics. 2013; 25(9): 1409–13. doi: 10.1017/S1041610213000744
31. Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005; 76 (Suppl V):v2–v7. doi: 10.1136/jnnp.2005.082867.
32. United Nations, Department of Economic and Social Affairs, Population Division World Population Prospects. 2019, Volume II: Demographic Profiles
33. Brookmeyer R, et al. Projections of Alzheimer’s Disease in the United States and the Public Health Impact of Delaying Disease Onset. Am J Public Health. 1998; 88(9): 1337–1342. doi: 10.2105/ajph.88.9.1337.
34. Census provisional population totals. The Registrar General & Census Commissioner, India. Retrieved 14 February 2013. https://doi.org/10.53555/sshr.v3i4.1962
35. Mehra A, et al. Association of mild cognitive impairment and metabolic syndrome in patients with hypertension. Asian Journal of Psychiatry. 2020; 53. doi: 10.1016/j.ajp.2020.102185
36. Ward A, et al. Mild cognitive impairment: Disparity of incidence and prevalence estimates. Alzheimer’s and Dementia. 2012; 8(1): 14–21. doi: 10.1016/j.jalz.2011.01.002.
37. Mohan D, et al. A cross-sectional study to assess prevalence and factors associated with mild cognitive impairment among older adults in an urban area of Kerala, South India. BMJ Open. 2019; 9(3): 9:e025473. doi: 10.1136/bmjopen-2018-025473.
38. Krishnamoorthy Y, et al. Screening for mild cognitive impairment among noncommunicable disease patients attending a rural primary health center in Puducherry, South India. Journal of Natural Science, Biology and Medicine. 2019; 10(1): 77–81. http://dx.doi.org/10.4103/jnsbm.JNSBM_90_18
39. Elkahloun AG, et al. An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease. Alzheimer’s Research and Therapy. 2016; 8(5): 1-18. https://doi.org/10.1186%2Fs13195-015-0167-5.
40. Tsukuda K, et al. Cognitive Deficit in Amyloid- β–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-γ Activation. Hypertension. 2009; 54: 782-787. doi: 10.1161/Hypertensionaha.109.136879.
41. Wang J, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease J Clin. Invest. 2007; 117: 3393–3402. doi: 10.1172/JCI31547.
42. Zijlstra LE, et al. The association of kidney function and cognitive decline in older patients at risk of cardiovascular disease: a longitudinal data analysis BMC Nephrology. 2020; 21. doi: 10.1186/s12882-020-01745-5.